Trexquant Investment LP Has $300,000 Holdings in MeiraGTx Holdings PLC $MGTX

Trexquant Investment LP increased its stake in shares of MeiraGTx Holdings PLC (NASDAQ:MGTX) by 12.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,318 shares of the company’s stock after buying an additional 4,970 shares during the quarter. Trexquant Investment LP owned about 0.06% of MeiraGTx worth $300,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Sanofi acquired a new stake in shares of MeiraGTx in the 4th quarter valued at approximately $74,284,000. Woodline Partners LP bought a new position in shares of MeiraGTx in the 4th quarter worth about $9,349,000. Erste Asset Management GmbH raised its position in shares of MeiraGTx by 17.9% in the 1st quarter. Erste Asset Management GmbH now owns 789,702 shares of the company’s stock worth $5,366,000 after acquiring an additional 120,000 shares in the last quarter. Invesco Ltd. increased its position in MeiraGTx by 1,628.7% in the 1st quarter. Invesco Ltd. now owns 350,401 shares of the company’s stock valued at $2,376,000 after buying an additional 330,131 shares in the last quarter. Finally, Northern Trust Corp raised its stake in MeiraGTx by 18.9% during the 4th quarter. Northern Trust Corp now owns 315,665 shares of the company’s stock worth $1,922,000 after buying an additional 50,267 shares during the period. Institutional investors and hedge funds own 67.48% of the company’s stock.

Insider Buying and Selling at MeiraGTx

In related news, CEO Alexandria Forbes sold 47,500 shares of MeiraGTx stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $7.97, for a total transaction of $378,575.00. Following the completion of the sale, the chief executive officer owned 1,361,483 shares of the company’s stock, valued at approximately $10,851,019.51. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Richard Giroux sold 24,000 shares of the firm’s stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $8.52, for a total value of $204,480.00. Following the sale, the chief financial officer owned 853,494 shares in the company, valued at $7,271,768.88. The trade was a 2.74% decrease in their position. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by company insiders.

MeiraGTx Price Performance

NASDAQ:MGTX opened at $7.65 on Wednesday. The firm has a market capitalization of $615.42 million, a price-to-earnings ratio of -3.75 and a beta of 1.29. MeiraGTx Holdings PLC has a 52-week low of $3.86 and a 52-week high of $8.98. The stock has a fifty day moving average of $7.94 and a 200 day moving average of $6.82. The company has a debt-to-equity ratio of 26.29, a quick ratio of 0.88 and a current ratio of 0.88.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.04. The company had revenue of $3.69 million during the quarter, compared to analyst estimates of $8.00 million. MeiraGTx had a negative return on equity of 314.44% and a negative net margin of 415.39%. On average, research analysts expect that MeiraGTx Holdings PLC will post -1.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MGTX has been the subject of several research reports. Chardan Capital reissued a “buy” rating and issued a $35.00 price target on shares of MeiraGTx in a research report on Friday, August 15th. Wall Street Zen raised MeiraGTx from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, MeiraGTx currently has a consensus rating of “Buy” and an average price target of $24.00.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.